--Arthur Caplan (NYU) Covid-19: The Ethics of EUAs and Vaccine Development (Starts at 00:01:00) Abstract: Should early approval be given for the first vaccine candidates to prevent harm from covid? Who will decide this issue—companies, DSMBs, states, FDA or all of these. If early access is desirable should it be under an EUA or an EA and what is the difference? And if there is early access who goes first? Will early access jeopardize ongoing and soon to start phase 3 trials? --Monique K. Mansoura (MITRE Corporation) An Industrial Base for Global Health Security – A 21st Century ImperativeVaccine ethics challenges (Starts at 00:18:30) --Jim Robinson (CEPI) Incentivizing Late-Stage Vaccine Development and Manufacturing for Epidemic and Pandemic Response (Starts at 00:52:00) --Rena Conti (Boston University) Generic drug repurposing for National Security and Health Improvement – the COVID-19 Pandemic and Beyond (Starts at 01:33:00) Abstract: COVID19 is an all-out attack on our lives and our economy. We need a proportionate all-in response. Generic drug repurposing should be part of that response. Authors: Rena Conti, Associate Professor, Department of Markets, Public Policy and Law, Questrom School of Business Boston University Susan Athey, Economics of Technology Professor, Stanford Graduate School of Business Richard Frank, Professor of Health Economics, Harvard Medical School Jonathan Gruber, Ford Professor of Economics, MIT